Supplementary Figure S5 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

Ahmad A. Tarhini; Alyssa Obermayer; Sandra J. Lee; William A. LaFramboise; F. Stephen Hodi; Arivarasan Karunamurthy; Islam Eljilany; Dung‐Tsa Chen; Patrick Hwu; Issam El Naqa; Howard Streicher; Vernon K. Sondak; Walter J. Storkus; Lisa H. Butterfield; Timothy I. Shaw; John M. Kirkwood

doi:10.1158/1078-0432.29760698

August 1, 2025

Supplementary Figure S5 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: An integrative immune signature significantly improves predictive power for survival in high-risk melanoma patients.
KEY EVIDENCE: Kaplan-Meier curves illustrate overall survival and recurrence-free survival differences based on Cox regression analysis.
APPROACH: The study utilized Cox proportional hazards regression to analyze prioritized features affecting melanoma outcomes.
SIGNIFICANCE: These findings could enhance adjuvant immunotherapy strategies, potentially improving patient prognoses in melanoma.

Implication

Kaplan-Meier analysis shows recurrence-free survival linked to immune signature in melanoma patients, suggesting better treatment outcomes.

Abstract

Supplementary Figure S5. Kaplan-Meier overall survival (OS) and recurrence-free survival (RFS) curves of 4 prioritized high-risk and low-risk features determined by the Cox proportional hazards regression analysis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tarhini et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0200 https://doi.org/10.1158/1078-0432.29760698

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S5 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S5 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers